Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

China SXT Pharmaceuticals (SXTC) Common Equity: 2017-2025

Historic Common Equity for China SXT Pharmaceuticals (SXTC) over the last 9 years, with Mar 2025 value amounting to $15.4 million.

  • China SXT Pharmaceuticals' Common Equity rose 247.50% to $116.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $116.0 million, marking a year-over-year increase of 247.50%. This contributed to the annual value of $15.4 million for FY2025, which is 10.83% up from last year.
  • Per China SXT Pharmaceuticals' latest filing, its Common Equity stood at $15.4 million for FY2025, which was up 10.83% from $13.9 million recorded in FY2024.
  • In the past 5 years, China SXT Pharmaceuticals' Common Equity registered a high of $16.4 million during FY2022, and its lowest value of $13.9 million during FY2024.
  • Moreover, its 3-year median value for Common Equity was $14.7 million (2023), whereas its average is $14.7 million.
  • As far as peak fluctuations go, China SXT Pharmaceuticals' Common Equity spiked by 69.78% in 2021, and later declined by 10.55% in 2023.
  • Over the past 5 years, China SXT Pharmaceuticals' Common Equity (Yearly) stood at $16.0 million in 2021, then rose by 2.90% to $16.4 million in 2022, then decreased by 10.55% to $14.7 million in 2023, then declined by 5.18% to $13.9 million in 2024, then grew by 10.83% to $15.4 million in 2025.